Related Experiment Video
Updated: Aug 8, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Rheumatologic aspects of lysosomal storage diseases
Bernhard Manger1, Eugen Mengel, Roland M Schaefer
1Department of Medicine III, Institute for Clinical Immunology and Rheumatology, Friedrich-Alexander-University Erlangen-Nurnberg, Krankenhausstrasse 12, 91054, Erlangen, Germany. bernhard.manger@med3.imed.uni-erlangen.de
Abstract:
Lysosomal storage diseases are rare metabolic disorders, some of which can now be treated using enzyme replacement therapies. Because the time point of treatment initiation significantly influences the outcome in Gaucher disease, Fabry disease, and mucopolysaccharidosis type I, early diagnosis is of utmost importance. All three disorders can present with musculoskeletal symptoms in early stages, therefore, the rheumatologist may be the first to be contacted by these patients. Here, we present three characteristic lysosomal storage disease cases to increase awareness in the rheumatological community of the typical symptom constellations associated with these rare but treatable disorders.
Related Concept Videos
Lysosomal Hydrolases
Rheumatic Heart Disease I: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myasthenia Gravis ll: Pathophysiology
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Chronic Inflammation: Introduction